GSK to buy food allergy drug maker RAPT in $2.2bn deal

GSK, the UK’s second-biggest drugmaker, has unveiled a $2.2bn (£1.6bn) deal to acquire a Californian biotech company which is developing a drug that aims to protect against severe food allergies such as nuts, milk and eggs.It is the first large deal announced by GSK’s new chief executive, Luke Miels, who joined the London-based company in 2017 as chief commercial officer and took the reins from Emma Walmsley at the start of the year.RAPT Therapeutics is developing therapies for people with inflammatory and ...